Will Pfizer Inc. (PFE) Reach $39

Pfizer . (NYSE:PFE) is trending after Morgan Stanley raised its price target for the stock to $39, citing valuation and growth prospects. Morgan Stanley ’s report said that Pfizer ’s breast cancer drug Ibrance has excellent growth prospects, mainly because Ibrance’s competitors are facing pressure in and outside the US. Pfizer will also be a big benefactor of the latest tax reform announced by the US government.

It’s important to note that Ibrance has still a very little presence in emerging markets. Aside from Ibrance, Pfizer is working on about 30 drugs, out of which 15 have the potential to become blockbusters, according to the company’s CEO.

Over the current book year the total revenue will be 52,72 billion USD (consensus estimates). This is slightly lower than 2016's revenue of 52,82 billion USD.

Historical revenues and results Pfizer plus estimates 2017

The analysts expect for 2017 a net profit of 15,47 billion USD. The majority of the analysts expects for this year a profit per share of 2,56 USD. Based on this the price/earnings-ratio is 14,06.

Huge dividend Pfizer

For this year the analysts expect a dividend of 1,28 USD per share. Pfizer 's dividend yield thus equals 3,56 percent. The average dividend yield of the pharmaceutical companies equals a low 0,41 percent.

Latest estimates around 38 USD

The latest 3 recommendations for the pharmaceutical company were provided by Morgan Stanley , Sanford C. Bernstein & Co and Jefferies & Co..

Based on the current number of shares Pfizer 's market capitalization equals 222,3 billion USD.

On Thursday the stock closed at 36 USD.

Historical stock prices Pfizer period 2007-2017

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.